English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background   Drug survival is a marker for treatment sustainability in chronic diseases such as psoriasis.    Objective  The aim of these analyses was to assess survival of biologic treatments in the PSOriasis Longitudinal Assessment and Registry ( PSOLAR ).    Methods   PSOLAR  is a large, prospective, international, disease‐based registry of patients with psoriasis receiving (or eligible for) systemic therapy in a real‐world setting. Drug survival is defined as the time from initiation to discontinuation (stop/switch) of biologic therapy on registry. The number of patients who discontinued each treatment and the duration of therapy were recorded. Using Kaplan–Meier survival curves and Cox‐regression analyses [hazard ratios ( HR ) and 95% confidence intervals ( CI s)], time to discontinuation was compared across cohorts undergoing first‐, second‐ or third‐line treatment with ustekinumab, infliximab, adalimumab or etanercept.    Results  As of the 2013 data cut, 12 095 patients with psoriasis were enrolled in  PSOLAR . Of the 4000 patients initiating any new biologic therapy, approximately 3500 started a first‐line, second‐line or third‐line biologic therapy during the registry. Lack of effectiveness was the most common reason for discontinuation across biologic therapies. Based on the multivariate analysis, significantly shorter times to discontinuation were observed for infliximab [ HR  (95% CI ) = 2.73 (1.48 – 5.04),  P  = 0.0014]; adalimumab [4.16 (2.80 – 6.20),  P  < 0.0001]; and etanercept [4.91 (3.28 – 7.35)  P  < 0.0001] compared with ustekinumab [reference treatment]) for first‐line biologic use; results were similar for treatment effects for second/third‐line therapies. Although limited in power, analyses in patients with concurrent psoriatic arthritis confirmed by a rheumatologist reflect observations in the overall psoriasis population.    Conclusion  Drug survival was superior for ustekinumab compared with infliximab, adalimumab and etanercept in patients with psoriasis.

journal of the european academy of dermatology and venereology

Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)